Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of 3-carboxylic acid tetrahydroisoquinoline derivatives in the preparation of drugs for treating dopaminergic neurological diseases

A tetrahydroisoquinoline, dopaminergic technology, applied in the field of biomedicine, can solve problems such as rare pharmacological activity, and achieve the effects of enhancing and brain bioavailability and reducing the rate of LD degradation

Active Publication Date: 2018-01-02
苏州必益必诚医药科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

3-Carboxylic acid tetrahydroisoquinolines are simple amino acids, but there are few reports on their pharmacological activities, especially neuropharmacological activities.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 3-carboxylic acid tetrahydroisoquinoline derivatives in the preparation of drugs for treating dopaminergic neurological diseases
  • Application of 3-carboxylic acid tetrahydroisoquinoline derivatives in the preparation of drugs for treating dopaminergic neurological diseases
  • Application of 3-carboxylic acid tetrahydroisoquinoline derivatives in the preparation of drugs for treating dopaminergic neurological diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Preparation of 3-Carboxylic Acid Tetrahydroisoquinoline Derivatives from Cat Bean

[0022] The medicinal material of cat bean (MD20091101) was collected in Baise, Guangxi, and was identified as the seed of Mucuna pruriens var. utilis A. Cheval. Take 3.0 kg of dried cat bean, grind it into coarse powder, extract it with acetone at room temperature for 24 hours to remove the oil, and continue to extract the dregs with methanol for 2 times under reflux, each time for 2 hours, and recover methanol to obtain 214 g of cat bean extract (MDE). Take MDE104g, after repeated medium-pressure silica gel column chromatography, elute with chloroform-methanol-0.5% acetic acid 7:3:0.5 (volume ratio) to obtain MD02 (30mg); continue to elute with 6.5:3.5:0.5 to obtain MD01 (200 mg), MD03 (12 mg); continue to elute at 5:5:0.5, and obtain MD04 (15 mg), LD (35 mg); in sequence. The chemical structures of MD01-MD04 have been 1 H-NMR, IR, MS and other spectral analysis, compared with the lit...

Embodiment 2

[0024] Chemical Synthesis of (3S)-3-carboxy-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (MD03)

[0025] Take 100mg of levodopa, add appropriate amount of 0.1N hydrochloric acid to dissolve, neutralize with sodium hydroxide solution, add 0.35ml of 40% formaldehyde solution, shake and mix, stir and react at 30°C for 72h. The reaction solution was centrifuged (4000r / min, 10min), and the precipitate was collected and dried under reduced pressure to obtain 20 mg of the target product.

Embodiment 3

[0027] Chemical Synthesis of 1-methyl-3-carboxy-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline

[0028]Take 100mg of levodopa, add appropriate amount of 0.1N hydrochloric acid to dissolve, neutralize with sodium hydroxide solution, add 0.35ml of acetaldehyde solution, shake and mix, stir and react at 30°C for 72h. The reaction solution was centrifuged (4000r / min, 10min), and the precipitate was collected and dried under reduced pressure to obtain 50mg of the product. The product was further separated by HPLC. The chromatographic conditions were: ODS chromatographic column, 20×250mm, 10% methanol-0.1% acetic acid as the mobile phase, to obtain 1α-methyl-3-carboxy-6,7-dihydroxy-1 , 15 mg of 2,3,4-tetrahydroisoquinoline, 8 mg of 1β-methyl-3-carboxy-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of 3-carboxylic acid tetrahydroisoquinoline derivatives in the preparation of medicines for treating dopaminergic neurological diseases. 3‑Carboxylic acid tetrahydroisoquinoline derivatives can be isolated from cat pea plants, or via Pictet‑Spengler via the amino acid precursors phenylalanine, tyrosine, or levodopa with the corresponding aldehydes or ketones Condensation chemical synthesis. Rat animal experiments show that when the derivative components are administered in combination with the levodopa component, the drug concentration of levodopa in blood and brain tissue can be significantly increased, thereby improving the bioavailability of levodopa. In addition, such derivative components significantly inhibited morphine-induced high spontaneous movement in rats, and could pass through the blood-brain barrier, suggesting that such components can regulate dopaminergic nerve function. The 3-carboxylic acid tetrahydroisoquinoline derivatives of the present invention can be used to treat dopaminergic neurological diseases such as Parkinson's disease and psychosis.

Description

technical field [0001] The present invention relates to the application of a 3-carboxylic acid tetrahydroisoquinoline derivative, more specifically, the application of the 3-carboxylic acid tetrahydroisoquinoline derivative in the preparation of drugs for the treatment of dopaminergic neurological diseases, belonging to biological field of medicine. Background technique [0002] Parkinson's disease is one of the most common neurodegenerative disorders among older adults, affecting approximately 1.7 percent of those over 65 and 2 percent of those over 80. About 18 million people in the world suffer from this disease at present, and there are about 1.7 million patients in my country. The main pathological changes of Parkinson's disease are the progressive degeneration and death of dopaminergic neurons in the substantia nigra of the midbrain, which leads to the loss of the motor regulation function of the nervous system in this part, and the appearance of resting tremor, muscl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/472A61P25/16A61P25/18A61P25/00A61K31/198
Inventor 刘江云谭蓓蓓窦冕郑龙太杨世林
Owner 苏州必益必诚医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com